Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Pharmacol Drug Dev ; 11(9): 1099-1109, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-35819310

RESUMO

The pharmacokinetics (PK) and safety of ofatumumab and bendamustine alone and in combination were evaluated in patients with treatment-naive or relapsed indolent B-cell non-Hodgkin lymphoma (iNHL). Patients were randomly assigned to ofatumumab and bendamustine or ofatumumab alone. Ofatumumab PK concentration profiles and parameters were similar, alone or in combination with bendamustine. A decrease of 14% in the maximum observed plasma concentration (Cmax ) and 15% in the area under the plasma concentration-time curve (AUC) from time 0 to the last measurable concentration sampling time (AUClast ) was observed for ofatumumab coadministered with bendamustine, which was not considered clinically relevant. Bendamustine PK concentration profiles and parameters were similar with or without ofatumumab. The most frequent treatment-related adverse event was infusion-related reaction in 53% in the combination arm and 47% in the ofatumumab arm. No relevant drug-drug interaction was observed between ofatumumab and bendamustine. Ofatumumab alone or in combination with bendamustine had a manageable safety profile.


Assuntos
Anticorpos Monoclonais Humanizados , Cloridrato de Bendamustina , Linfoma de Células B , Anticorpos Monoclonais Humanizados/efeitos adversos , Cloridrato de Bendamustina/efeitos adversos , Quimioterapia Combinada/efeitos adversos , Humanos , Linfoma de Células B/tratamento farmacológico , Linfoma de Células B/patologia
2.
Blood Cancer J ; 9(12): 98, 2019 12 04.
Artigo em Inglês | MEDLINE | ID: mdl-31801940

RESUMO

We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years) or observation. Median follow-up duration was 40.9 months. Median progression-free survival was 34.2 and 16.9 months for ofatumumab and observation arms, respectively, (hazard ratio, 0.55 [95% confidence interval, 0.43-0.70]; P < 0.0001). Median time to next treatment for ofatumumab and observation arms, respectively, was 37.4 and 27.6 months (0.72 [0.57-0.91]; P = 0.0044). Overall survival was similar in both arms; median was not reached (0.99 [0.72-1.37]). Grade ≥ 3 adverse events occurred in 62% and 51% of patients in ofatumumab and observation arms, respectively, the most common being neutropenia (23% and 10%), pneumonia (13% and 12%) and febrile neutropenia (6% and 4%). Up to 60 days after the last treatment, four deaths were reported in the ofatumumab arm versus six in the observation arm, none considered related to ofatumumab. Ofatumumab maintenance significantly prolonged progression-free survival in patients with relapsed CLL and was well tolerated.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Leucemia Linfocítica Crônica de Células B/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Antineoplásicos Imunológicos/administração & dosagem , Antineoplásicos Imunológicos/efeitos adversos , Feminino , Humanos , Leucemia Linfocítica Crônica de Células B/diagnóstico , Quimioterapia de Manutenção , Masculino , Pessoa de Meia-Idade , Recidiva , Retratamento , Resultado do Tratamento
3.
Eur Neuropsychopharmacol ; 24(8): 1257-68, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24880753

RESUMO

Almorexant is a dual orexin receptor antagonist (DORA) with sleep-enabling effects in humans. Insomnia is often associated with mental health problems, including depression. Hence, potential interactions with antidepressants deserve attention. Desipramine was selected as a model drug because it is mainly metabolized by CYP2D6, which is inhibited by almorexant in vitro. A single-center, randomized, placebo-controlled, two-way crossover study in 20 healthy male subjects was conducted to evaluate the pharmacokinetic and pharmacodynamic interactions between almorexant and desipramine. Almorexant 200mg or matching placebo (double-blind) was administered orally once daily in the morning for 10 days, and a single oral dose of 50mg desipramine (open-label) was administered on Day 5. Almorexant increased the exposure to desipramine 3.7-fold, suggesting that almorexant is a moderate inhibitor of desipramine metabolism through inhibition of CYP2D6. Conversely, desipramine showed no relevant effects on the pharmacokinetics of almorexant. Pharmacodynamic evaluations indicated that almorexant alone reduced visuomotor coordination, postural stability, and alertness, and slightly increased calmness. Desipramine induced a reduction in subjective alertness and an increase in pupil/iris ratio. Despite the increase in exposure to desipramine, almorexant and desipramine in combination showed the same pharmacodynamic profile as almorexant alone, except for prolonging reduced alertness and preventing the miotic effect of almorexant. Co-administration also prolonged the mydriatic effect of desipramine. Overall, repeated administration of almorexant alone or with single-dose desipramine was well tolerated. The lack of a relevant interaction with antidepressants, if confirmed for other DORAs, would be a key feature for a safer class of hypnotics.


Assuntos
Acetamidas/farmacocinética , Antidepressivos Tricíclicos/farmacocinética , Sangue/efeitos dos fármacos , Citocromo P-450 CYP2D6/genética , Desipramina/farmacocinética , Isoquinolinas/farmacocinética , Antagonistas dos Receptores de Orexina , Administração Oral , Adolescente , Adulto , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
4.
Drug Des Devel Ther ; 8: 397-403, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24812492

RESUMO

Almorexant, a dual orexin receptor antagonist, was investigated for the treatment of insomnia. The following observations initiated further formulation development: the active pharmaceutical ingredient (API) was sticking to the apparatus used during tablet compression; almorexant has an absolute bioavailability of 11.2%; and almorexant modestly decreased the latency to persistent sleep by 10.4 minutes in patients. Two randomized crossover studies were performed to investigate the pharmacokinetics of several new formulations in healthy subjects. In study I, the old "sticky" tablet was compared to two new formulations developed to prevent sticking: a qualitatively similar tablet but with a larger API crystal size and a tablet with 30% more excipients as well as a larger API crystal size. This latter formulation was available in two strengths. The geometric mean ratios and 90% confidence interval of the area under the curve (AUC) were within the bioequivalence range of 0.80-1.25 for the different comparisons between formulations. In study II, 100 mg of the reference tablet was compared to 25 and 50 mg of a liquid-filled hard gelatin capsule developed to increase the bioavailability of almorexant. The geometric mean ratios of the maximum concentration and AUC comparing the new 25 and 50 mg capsule formulations to the reference tablet did not exceed 0.25 and 0.50, respectively, indicating that the new capsule formulation did not increase the maximum concentration of or the total exposure to almorexant. In conclusion, a new tablet was developed but formulation development aimed at increasing the bioavailability of almorexant failed.


Assuntos
Acetamidas/farmacocinética , Isoquinolinas/farmacocinética , Antagonistas dos Receptores de Orexina , Acetamidas/efeitos adversos , Acetamidas/química , Adulto , Química Farmacêutica , Estudos Cross-Over , Feminino , Humanos , Isoquinolinas/efeitos adversos , Isoquinolinas/química , Masculino , Pessoa de Meia-Idade , Comprimidos
5.
CNS Drugs ; 28(4): 361-72, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24627301

RESUMO

BACKGROUND: Dual orexin receptor antagonists (DORAs) enable initiation and maintenance of sleep in patients with primary insomnia. Blockade of the orexin system has shown reduction of drug-seeking behavior in animal studies, supporting the role of orexin antagonism as a novel approach for treating substance abuse. Since hypnotics are traditionally associated with misuse, a lack of abuse liability of DORAs would offer significant benefits over current therapies for sleep disorders. METHODS: In this randomized, crossover, proof-of-concept study, single oral doses of the DORA almorexant (200, 400, and 1,000 mg) were administered to healthy subjects with previous non-therapeutic experience with central nervous system depressants and were compared with placebo and single oral doses of zolpidem (20 and 40 mg), a benzodiazepine-like drug. Subjective measures of abuse potential (visual analog scales [VAS], Addiction Research Center Inventory, and Subjective Drug Value) and objective measures (divided attention [DA]) were evaluated over 24 h post-dose in 33 evaluable subjects. RESULTS: Drug Liking VAS peak effect (E max; primary endpoint) was significantly higher for all doses of almorexant and zolpidem compared with placebo (p<0.001). Almorexant 200 mg showed significantly less 'Drug Liking' than both zolpidem doses (p<0.01), and almorexant 400 mg had smaller effects than zolpidem 20 mg (p<0.05), while almorexant 1,000 mg was not different from either zolpidem dose. Results were similar for other subjective measures, although almorexant generally showed smaller negative and perceptual effects compared with zolpidem. Almorexant also showed less cognitive impairment compared with zolpidem on most DA endpoints. CONCLUSION: This study in humans investigating single doses of almorexant is the first to explore and show abuse liability of a DORA, a class of compounds that is not only promising for the treatment of sleep disorders, but also of addiction.


Assuntos
Acetamidas/administração & dosagem , Hipnóticos e Sedativos/administração & dosagem , Drogas Ilícitas/efeitos adversos , Isoquinolinas/administração & dosagem , Antagonistas dos Receptores de Orexina , Piridinas/administração & dosagem , Acetamidas/farmacocinética , Adolescente , Adulto , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Hipnóticos e Sedativos/farmacocinética , Isoquinolinas/farmacocinética , Masculino , Pessoa de Meia-Idade , Receptores de Orexina/metabolismo , Piridinas/farmacocinética , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/metabolismo , Adulto Jovem , Zolpidem
6.
J Pharm Sci ; 103(5): 1548-56, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24604243

RESUMO

Almorexant, a tetrahydroisoquinoline orexin receptor antagonist and first representative of a new class of compounds for the treatment of insomnia, is a substrate of the cytochrome P450 3A4 isoenzyme (CYP3A4). Two randomized two-way crossover studies were performed in healthy subjects investigating the pharmacokinetic interaction between almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. When administered as a single dose of 100 mg almorexant during steady state of ketoconazole (400 mg once daily for 14 days) or diltiazem treatment (300 mg once daily for 11 days), the exposure to almorexant was 10.5- and 3.5-fold, respectively, greater when compared with almorexant alone. Exposure to the phenol metabolites M3 and M8 increased in the presence of the CYP3A4 inhibitors, whereas that to M6 (dealkylated metabolite) decreased. Concomitant ketoconazole decreased formation of the dehydrogenated metabolite M5 and diltiazem increased concentrations of this metabolite. Higher almorexant exposure was associated with an increased incidence of typical almorexant-related adverse events such as fatigue (both studies) and somnolence (ketoconazole study only). The present results indicate that dose adaptation must be considered when almorexant would be coadministered with inhibitors of CYP3A4.


Assuntos
Acetamidas/farmacocinética , Citocromo P-450 CYP3A/metabolismo , Diltiazem/farmacocinética , Inibidores Enzimáticos/farmacocinética , Isoquinolinas/farmacocinética , Cetoconazol/farmacocinética , Antagonistas dos Receptores de Orexina , Adulto , Área Sob a Curva , Estudos Cross-Over , Interações Medicamentosas/fisiologia , Humanos , Masculino , Adulto Jovem
7.
Eur J Pharm Sci ; 49(5): 836-44, 2013 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-23770377

RESUMO

This single-dose study aimed at investigating the effect of different degrees of hepatic impairment on the pharmacokinetics (PK), metabolism, and tolerability of almorexant, a first-in-class dual orexin receptor antagonist. Subjects with mild (Child-Pugh A, Group A, n=8) and moderate (Child-Pugh B, Group B, n=9) liver impairment and subjects with normal liver function (Group DA and DB, both n=9) received a dose of 100mg almorexant. PK parameters of almorexant and its four primary metabolites were determined. Almorexant exposure increased with severity of hepatic impairment. Geometric mean ratios (90% confidence interval) of AUC0-∞ were 2.8 (1.5-5.4), 7.2 (3.7-14.1), and 3.3 (1.7-6.4) comparing A vs. DA, B vs. DB, and B vs. A, respectively. The four metabolic pathways involved in the formation of the primary metabolites were affected in a different fashion. Geometric mean AUC0-∞ ratios comparing A vs. DA were 6.9, 1.1, 1.4, and 3.6 for M3, M5, M6, and M8, respectively. Comparing B vs. DB the corresponding figures were 7.3, 2.0, 5.4, and 1.3, respectively. Significant effects of hepatic impairment on the PK of almorexant suggested the need for dose adjustment in subjects with mild hepatic impairment and did not support its use in subjects with moderate or severe hepatic impairment.


Assuntos
Acetamidas/farmacocinética , Isoquinolinas/farmacocinética , Hepatopatias/metabolismo , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas dos Receptores de Orexina , Ligação Proteica
8.
Drugs R D ; 13(2): 145-51, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23737453

RESUMO

BACKGROUND AND OBJECTIVE: Almorexant is the first representative of the new class of orexin receptor antagonists, which could become a new treatment option for insomnia. The present study investigated the potential interaction between almorexant and warfarin. METHODS: In this open-label, two-way crossover, drug-drug interaction study, healthy male subjects received, in a randomized fashion, almorexant 200 mg once daily for 10 days and a single dose of 25 mg warfarin co-administered on day 5 (treatment A) and a single dose of 25 mg warfarin on day 1 (treatment B). Serial blood samples for warfarin pharmacokinetics and pharmacodynamics were drawn during both treatments. RESULTS: Of the 14 enrolled subjects, one withdrew due to an adverse event and 13 completed the study. Almorexant had no effect on the pharmacokinetics of warfarin. The geometric mean ratios (90% confidence interval) for the area under the plasma concentration-time curve to infinity (AUC0-∞) of S- and R-warfarin were 0.99 (0.89, 1.09) and 1.05 (0.95, 1.16), respectively, and for the maximum plasma concentration (Cmax) were 0.99 (0.86, 1.14) and 1.00 (0.88, 1.13), respectively. The main pharmacodynamic variable was the AUC for the international normalized ratio (AUCINR). Almorexant had no effect on this variable as demonstrated by a geometric mean ratio of 0.99 (0.82, 1.19). Secondary pharmacodynamic variables including maximum effect (Emax), the time to the maximum INR, and factor VII plasma concentrations were also not affected by almorexant. CONCLUSION: No dose adjustment of warfarin is necessary when concomitantly administered with almorexant.


Assuntos
Acetamidas/farmacologia , Acetamidas/farmacocinética , Anticoagulantes/farmacologia , Anticoagulantes/farmacocinética , Hipnóticos e Sedativos/farmacologia , Isoquinolinas/farmacologia , Isoquinolinas/farmacocinética , Varfarina/farmacologia , Varfarina/farmacocinética , Adulto , Estudos Cross-Over , Interações Medicamentosas , Fator VII/metabolismo , Voluntários Saudáveis , Humanos , Hipnóticos e Sedativos/farmacocinética , Coeficiente Internacional Normatizado , Masculino
9.
J Clin Psychopharmacol ; 33(3): 363-70, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23609389

RESUMO

Sleep disorders are common in the elderly population. Orexin receptor antagonism has been proposed as a new sleep-enabling approach to treat insomnia. The tolerability, pharmacokinetics, and pharmacodynamics of ascending single doses of almorexant, a dual orexin receptor antagonist, were investigated in healthy elderly male and female subjects. In this double-blind, placebo- and active-controlled study, each dose (100, 200, and 400 mg) was investigated in a separate group of 12 subjects (almorexant, placebo, and zolpidem 10 mg in an 8:2:2 ratio). Morning doses of almorexant were well tolerated. As expected for sleep-enabling compounds, somnolence and fatigue were frequently reported. Other adverse events included headache and nausea. Muscular weakness was reported at a higher incidence only with the highest almorexant dose. The pharmacokinetic profile of almorexant was characterized by a median time to the maximum concentration of 1.5 hours, quick disposition with a distribution half-life of 1.6 hours, and rapidly decreasing concentrations to approximately 20% of the maximum concentration over 8 hours, with a terminal half-life of 32 hours. Objective pharmacodynamic measures showed decreases in saccadic peak velocity and adaptive tracking performance and increases in body sway with the 400-mg dose of almorexant. Subjective assessments revealed a dose-dependent decrease in alertness. Almorexant had no effects on mood, calmness, subjective internal and external perception, and feeling high. These findings provide a solid basis to study the effects of almorexant in elderly patients with insomnia.


Assuntos
Acetamidas/administração & dosagem , Isoquinolinas/administração & dosagem , Piridinas/farmacocinética , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores de Neuropeptídeos/antagonistas & inibidores , Acetamidas/efeitos adversos , Acetamidas/farmacocinética , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Meia-Vida , Humanos , Isoquinolinas/efeitos adversos , Isoquinolinas/farmacocinética , Masculino , Pessoa de Meia-Idade , Receptores de Orexina , Piridinas/efeitos adversos , Piridinas/farmacologia , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Zolpidem
10.
Drug Metab Dispos ; 41(5): 1046-59, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23431113

RESUMO

Almorexant [(2R)-2-{(1S)-6, 7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide], a tetrahydroisoquinoline derivative, is a dual orexin receptor antagonist with sleep-promoting properties in both animals and humans. This study investigated the disposition, metabolism, and elimination of almorexant in humans. After oral administration of a 200-mg dose of ¹4C-almorexant, almorexant was rapidly absorbed (Tmax = 0.8 hour), and the apparent terminal half-life (t(1/2)) was 17.8 hours. The radioactive dose was almost completely recovered with 78.0% of the administered radioactive dose found in feces and 13.5% in urine. Unchanged almorexant was not found in urine and represented 10% of the administered dose in feces. In total, 47 metabolites were identified of which 21 were shown to be present in plasma. There are four primary metabolites, the isomeric phenols M3 and M8, formed by demethylation, the aromatic isoquinolinium ion M5, formed by dehydrogenation, and M6, formed by oxidative dealkylation with loss of the phenylglycine moiety. Most of the subsequent products are formed by permutations of these primary metabolic reactions followed by conjugation of the intermediate phenols with glucuronic or sulfonic acid. The percentage of dose excreted in urine or feces for any of the metabolites did not exceed 10% of the administered radioactive dose, nor did any of the metabolites represent more than 10% of the total drug-related exposure. In conclusion, after rapid absorption, almorexant is extensively metabolized, and excretion of metabolites in feces is the predominant route of elimination in humans.


Assuntos
Acetamidas/farmacologia , Isoquinolinas/farmacologia , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores de Neuropeptídeos/antagonistas & inibidores , Acetamidas/administração & dosagem , Administração Oral , Adulto , Cromatografia Líquida , Meia-Vida , Humanos , Isoquinolinas/administração & dosagem , Masculino , Receptores de Orexina , Espectrometria de Massas em Tandem
11.
Eur J Clin Pharmacol ; 69(6): 1235-45, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23334403

RESUMO

PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual orexin receptor antagonist almorexant. METHODS: Pharmacokinetic interactions were investigated (n = 14 healthy male subjects in two treatment groups) between almorexant at steady-state when administered either concomitantly or 2 h after administration of single doses of simvastatin (40 mg) or atorvastatin (40 mg). RESULTS: Almorexant dose-dependently increased simvastatin exposure (AUC0-∞) when administered concomitantly [geometric mean ratios (90 % CI): 2.5 (2.1, 2.9) (100 mg), 3.9 (3.3, 4.6) (200 mg)], but not Cmax [3.7 (3.0, 4.5) for both doses]. Time-separated administration resulted in relevant reductions of the interaction [AUC0-∞: 1.4 (1.2, 1.7) (100 mg), 1.7 (1.5, 2.0) (200 mg); Cmax: 1.5 (1.3, 1.9) (100 mg), 1.9 (1.6, 2.4) (200 mg)]. Similar results were obtained for hydroxyacid simvastatin. Independent of almorexant dose and relative time of administration, AUC0-∞ and Cmax of atorvastatin increased (ratios ranged from 1.1 to 1.5). AUC0-∞ and Cmax of o-hydroxy atorvastatin decreased dose-independently [AUC0-∞: 0.8 (0.8, 0.9) (100 mg), 0.6 (0.5, 0.6) (200 mg); Cmax: 0.3 (0.3, 0.4) (100 mg), 0.2 (0.2, 0.3) (200 mg)] when atorvastatin was concomitantly administered. Cmax of o-hydroxy atorvastatin slightly decreased (0.8 for both doses) following time-separated administration; AUC0-∞ was unchanged. CONCLUSIONS: Whereas almorexant increased simvastatin exposure dose- and relative time of administration-dependently, atorvastatin exposure increased to a smaller extent and irrespective of dose and time. This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.


Assuntos
Acetamidas/administração & dosagem , Inibidores do Citocromo P-450 CYP3A , Inibidores Enzimáticos/administração & dosagem , Ácidos Heptanoicos/farmacocinética , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética , Hipnóticos e Sedativos/administração & dosagem , Intestinos/efeitos dos fármacos , Isoquinolinas/administração & dosagem , Fígado/efeitos dos fármacos , Pirróis/farmacocinética , Sinvastatina/farmacocinética , Acetamidas/sangue , Acetamidas/farmacocinética , Administração Oral , Adulto , Área Sob a Curva , Atorvastatina , Biotransformação , Citocromo P-450 CYP3A/metabolismo , Relação Dose-Resposta a Droga , Esquema de Medicação , Interações Medicamentosas , Alemanha , Meia-Vida , Ácidos Heptanoicos/administração & dosagem , Ácidos Heptanoicos/sangue , Humanos , Hidroxilação , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Inibidores de Hidroximetilglutaril-CoA Redutases/sangue , Hipnóticos e Sedativos/sangue , Hipnóticos e Sedativos/farmacocinética , Intestinos/enzimologia , Isoquinolinas/sangue , Isoquinolinas/farmacocinética , Fígado/enzimologia , Masculino , Taxa de Depuração Metabólica , Pirróis/administração & dosagem , Pirróis/sangue , Sinvastatina/administração & dosagem , Sinvastatina/sangue , Adulto Jovem
12.
Eur J Clin Pharmacol ; 69(3): 523-32, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22990330

RESUMO

PURPOSE: Pre-clinical experiments have shown that almorexant, a dual orexin receptor antagonist, is able to inhibit cytochrome P450 3A4 (CYP3A4). Therefore, a study was conducted to investigate the effects of multiple-dose almorexant on the pharmacokinetics of midazolam and simvastatin, two CYP3A4 model substrates. METHODS: Fourteen healthy male subjects were enrolled in an open-label, randomized, two-way crossover study. Treatment period A consisted of a single oral dose of 2 mg midazolam on day 1 and 40 mg simvastatin on day 3. In treatment period B, subjects received 200 mg almorexant once daily for 9 days together with a single oral dose of midazolam on day 7 and simvastatin on day 9. RESULTS: Concomitant administration of midazolam with almorexant at steady-state levels, achieved within 4-5 days, resulted in an increase of 1.2-fold [90 % confidence interval (CI) 1.0-1.4], 1.4-fold (90 % CI 1.2-1.6), and 1.3-fold (90 % CI 1.2-1.4) in the maximum plasma concentration (C(max)), area under the concentration-time curve from time 0 to infinity (AUC(0-∞)), and terminal half-life (t(1/2)), respectively, of midazolam; the time to peak plasma concentration (t(max)) was unchanged. Whereas C(max) and t(max) were not influenced by almorexant, the AUC(0-∞) of hydroxy-midazolam increased by 1.2-fold (90 % CI 1.1-1.4) and the t(1/2) by 1.3-fold (90 % CI 1.0-1.5). Concomitant administration of simvastatin with almorexant at steady-state resulted in an increase of 2.7-fold (90 % CI 2.0-3.7) and 3.4-fold (90 % CI 2.6-4.4) in C(max) and AUC(0-∞), respectively, for simvastatin; the t(1/2) and t(max) were unchanged. The C(max) and AUC(0-∞) of hydroxyacid simvastatin both increased by 2.8-fold, with 90 % CIs of 2.3-3.5 and 2.2-3.5, respectively; the t(max) increased by 2 h and the t(1/2) was unchanged. The urinary 6-ß-hydroxycortisol/cortisol ratio was unaffected by almorexant. CONCLUSIONS: Our results suggest that the observed interaction was caused by the inhibition of CYP3A4 activity, most probably at the gut level.


Assuntos
Acetamidas/farmacocinética , Inibidores do Citocromo P-450 CYP3A , Inibidores Enzimáticos/farmacocinética , Isoquinolinas/farmacocinética , Midazolam/farmacocinética , Sinvastatina/farmacocinética , Acetamidas/administração & dosagem , Acetamidas/efeitos adversos , Acetamidas/sangue , Administração Oral , Adulto , Análise de Variância , Área Sob a Curva , Biotransformação , Estudos Cross-Over , Citocromo P-450 CYP3A/metabolismo , Esquema de Medicação , Interações Medicamentosas , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/sangue , Alemanha , Meia-Vida , Humanos , Hidrocortisona/análogos & derivados , Hidrocortisona/urina , Hidroxilação , Isoquinolinas/administração & dosagem , Isoquinolinas/efeitos adversos , Isoquinolinas/sangue , Masculino , Taxa de Depuração Metabólica , Midazolam/administração & dosagem , Midazolam/efeitos adversos , Midazolam/sangue , Pessoa de Meia-Idade , Sinvastatina/administração & dosagem , Sinvastatina/efeitos adversos , Sinvastatina/sangue , Especificidade por Substrato , Adulto Jovem
13.
Eur Neuropsychopharmacol ; 23(2): 107-17, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22658401

RESUMO

The orexin system plays a pivotal role in the regulation of the sleep/wake state. Almorexant is a selective, orally available dual orexin receptor antagonist. This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between almorexant (200 mg p.o.) and alcohol (0.6 g/L i.v. ethanol clamp for 5 h) using various cognitive and psychomotor performance tests in healthy subjects (n=20; 10 males and 10 females) in a 4-way crossover study. No effect of almorexant on ethanol PK was observed. The effects of ethanol on the PK of almorexant were limited, its exposure (AUC) increased by 21%; the median difference in tmax was 1.2 h; t1/2 and Cmax of almorexant were unchanged. Almorexant showed decreases in adaptive tracking performance, saccadic peak velocity, and subjective alertness as assessed by visual analog scale (VAS) of Bond and Lader, but had no or small effects on smooth pursuit eye movements, body sway, VAS for alcohol intoxication, and a memory test. Almorexant administered together with ethanol showed additive effects for adaptive tracking performance, saccadic peak velocity, subjective alertness and, possibly, calmness, but not on body sway, smooth pursuit, VAS for alcohol intoxication, or memory testing. To conclude, administration of almorexant together with ethanol was associated with additive effects for some of the measured cognitive and psychomotor performance tests. No indications of synergistic effects of almorexant and ethanol for any measured variable were observed.


Assuntos
Acetamidas/farmacologia , Sinergismo Farmacológico , Etanol/agonistas , Isoquinolinas/farmacologia , Antagonistas dos Receptores de Orexina , Desempenho Psicomotor/efeitos dos fármacos , Acetamidas/efeitos adversos , Acetamidas/farmacocinética , Acetamidas/uso terapêutico , Adolescente , Adulto , Afeto/efeitos dos fármacos , Intoxicação Alcoólica/tratamento farmacológico , Nível de Alerta/efeitos dos fármacos , Estudos Cross-Over , Método Duplo-Cego , Etanol/efeitos adversos , Etanol/farmacocinética , Etanol/farmacologia , Movimentos Oculares/efeitos dos fármacos , Feminino , Humanos , Isoquinolinas/efeitos adversos , Isoquinolinas/farmacocinética , Isoquinolinas/uso terapêutico , Masculino , Memória/efeitos dos fármacos , Pessoa de Meia-Idade , Postura
14.
J Psychopharmacol ; 26(8): 1071-80, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22695489

RESUMO

The objectives of this study were to investigate the multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual orexin receptor antagonist almorexant. Healthy subjects received daily doses of almorexant (100, 200, 400 or 1000 mg) or placebo in the morning for four days followed by two days with evening administration (Days 5-6). Each dose level was investigated in a new group of 10 subjects (eight active, two placebo, 1:1 sex). Dose-dependent increases in frequency and intensity were observed for somnolence and other adverse events. Pharmacokinetics at steady state showed rapid absorption, low concentrations eight hours post-dose, and minimal accumulation. Following evening, administration absorption was delayed and C(max) decreased. Almorexant at 400 and 1000 mg administered in the morning reduced vigilance, alertness, visuomotor coordination, and motor coordination assessed in a psychometric test battery. Polysomnography recordings following evening administration showed a trend towards shorter latency to sleep stages 3 and 4, and shorter latency to, and longer time in, rapid-eye-movement sleep at higher doses when compared to placebo. Whether these findings in healthy subjects translate into relevant sleep-enabling effects in insomnia patients needs to be investigated in future studies.


Assuntos
Acetamidas , Hipnóticos e Sedativos , Isoquinolinas , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores de Neuropeptídeos/antagonistas & inibidores , Acetamidas/efeitos adversos , Acetamidas/farmacocinética , Acetamidas/farmacologia , Adolescente , Adulto , Ondas Encefálicas/efeitos dos fármacos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Eletroencefalografia/efeitos dos fármacos , Feminino , Humanos , Hipnóticos e Sedativos/efeitos adversos , Hipnóticos e Sedativos/farmacocinética , Hipnóticos e Sedativos/farmacologia , Isoquinolinas/efeitos adversos , Isoquinolinas/farmacocinética , Isoquinolinas/farmacologia , Masculino , Receptores de Orexina , Polissonografia/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Fases do Sono/efeitos dos fármacos
15.
Pharmacology ; 89(1-2): 53-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22302127

RESUMO

BACKGROUND/AIMS: The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous formulation of almorexant in healthy subjects. METHODS: A pilot phase in 3 healthy male subjects, which preceded the main study, consisted of a single 30-min intravenous infusion of 10 mg almorexant. Its objectives were to ensure the tolerability of the intravenous formulation and to select the intravenous dose for the main study. The main study was a randomized, two-way crossover study in 20 healthy subjects (10 males and 10 females). Subjects received a single oral dose of 200 mg almorexant and a single 30-min intravenous infusion of 20 mg almorexant. RESULTS: All 23 subjects completed the study as planned. Almorexant was well tolerated; the main observed adverse events were somnolence and fatigue. A geometric mean total body clearance of 43 l/h (95% CI 39-47) and a volume of distribution of 683 liters (95% CI 552-845) were determined. The absolute oral bioavailability of almorexant was 11.2% (90% CI 9.6-13.1). CONCLUSION: Almorexant seems to possess a pronounced first-pass effect and metabolism.


Assuntos
Acetamidas/farmacocinética , Hipnóticos e Sedativos/farmacocinética , Isoquinolinas/farmacocinética , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores de Neuropeptídeos/antagonistas & inibidores , Acetamidas/administração & dosagem , Acetamidas/efeitos adversos , Administração Oral , Adolescente , Adulto , Disponibilidade Biológica , Feminino , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/efeitos adversos , Infusões Intravenosas , Isoquinolinas/administração & dosagem , Isoquinolinas/efeitos adversos , Masculino , Pessoa de Meia-Idade , Receptores de Orexina
16.
Pharmacology ; 88(3-4): 121-6, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21865769

RESUMO

BACKGROUND/AIMS: The aim of this study was to compare the pharmacokinetics and tolerability of single doses of the dual orexin receptor antagonist almorexant in Japanese and Caucasian healthy male subjects (n = 10 in each group, body weight matched ±5%). METHODS: Almorexant (200 mg) was administered in the morning in the fasted state. The pharmacokinetic parameters of almorexant were calculated by noncompartmental analysis from the plasma concentration data. RESULTS: The pharmacokinetics of almorexant in Japanese and Caucasian subjects were similar. The plasma concentration-time profile of almorexant was characterized by a rapid absorption and disposition. Peak plasma concentrations (C(max)) were reached at approximately 1.0 h in both ethnic groups. C(max) was 13% lower (ratio of geometric means [90% CI]: 0.87 [0.53, 1.43]), and the total exposure (AUC(0-)∞) was 15% lower (0.85 [0.54, 1.35]) in the Japanese subjects. There was no difference in the geometric mean ratio for t(1/2) between the two ethnic groups (1.03 [0.84, 1.25]). Almorexant was well tolerated in both ethnic groups. CONCLUSION: The pharmacokinetics and tolerability profiles of almorexant in Japanese and Caucasian healthy male subjects are similar. No dose adjustments for clinical studies with almorexant in Japanese subjects appear to be needed.


Assuntos
Acetamidas/farmacocinética , Isoquinolinas/farmacocinética , Acetamidas/efeitos adversos , Acetamidas/sangue , Adolescente , Adulto , Povo Asiático , Tontura/induzido quimicamente , Humanos , Isoquinolinas/efeitos adversos , Isoquinolinas/sangue , Masculino , Pessoa de Meia-Idade , Receptores de Orexina , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores de Neuropeptídeos/antagonistas & inibidores , Fases do Sono , População Branca , Adulto Jovem
19.
Nat Med ; 13(2): 150-5, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17259994

RESUMO

Orexins are hypothalamic peptides that play an important role in maintaining wakefulness in mammals. Permanent deficit in orexinergic function is a pathophysiological hallmark of rodent, canine and human narcolepsy. Here we report that in rats, dogs and humans, somnolence is induced by pharmacological blockade of both orexin OX(1) and OX(2) receptors. When administered orally during the active period of the circadian cycle, a dual antagonist increased, in rats, electrophysiological indices of both non-REM and, particularly, REM sleep, in contrast to GABA(A) receptor modulators; in dogs, it caused somnolence and increased surrogate markers of REM sleep; and in humans, it caused subjective and objective electrophysiological signs of sleep. No signs of cataplexy were observed, in contrast to the rodent, dog or human narcolepsy syndromes. These results open new perspectives for investigating the role of endogenous orexins in sleep-wake regulation.


Assuntos
Acetamidas/farmacologia , Hipotálamo Posterior/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Isoquinolinas/farmacologia , Neuropeptídeos/metabolismo , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores de Neuropeptídeos/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Sono REM/efeitos dos fármacos , Tetra-Hidroisoquinolinas/farmacologia , Acetamidas/farmacocinética , Animais , Cães , Eletroencefalografia , Feminino , Humanos , Hipotálamo Posterior/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular/fisiologia , Isoquinolinas/farmacocinética , Masculino , Neuropeptídeos/fisiologia , Receptores de Orexina , Orexinas , Ratos , Fatores Sexuais , Transdução de Sinais/fisiologia , Tetra-Hidroisoquinolinas/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...